{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:16:34Z","timestamp":1793891794593,"version":"4.8.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["2021CCG03"],"award-info":[{"award-number":["2021CCG03"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR-1933525"],"award-info":[{"award-number":["DMR-1933525"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Carbohydrate Polymers"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.carbpol.2022.119818","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T19:46:50Z","timestamp":1656877610000},"page":"119818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"special_numbering":"C","title":["Heparin: An old drug for new clinical applications"],"prefix":"10.1016","volume":"295","author":[{"given":"Peipei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianli","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Linhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00024677-200605040-00002","article-title":"The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy","volume":"5","author":"Abaterusso","year":"2006","journal-title":"Treatments in Endocrinology"},{"issue":"15","key":"10.1016\/j.carbpol.2022.119818_bb0010","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1074\/jbc.RA119.012419","article-title":"Heparin inhibits proinflammatory and promotes anti-inflammatory macrophage polarization under hyperglycemic stress","volume":"295","author":"Abbadi","year":"2020","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.carbpol.2022.119818_bb0015","first-page":"216","article-title":"Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma","volume":"62","author":"Abdelaty","year":"2007","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0020","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1038\/s41598-018-25480-y","article-title":"Heparin inhibits intracellular mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages","volume":"8","author":"Abreu","year":"2018","journal-title":"Scientific Reports"},{"issue":"14","key":"10.1016\/j.carbpol.2022.119818_bb0025","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2217\/nnm-2017-0127","article-title":"Heparin: New life for an old drug","volume":"12","author":"Alaez-Verson","year":"2017","journal-title":"Nanomedicine (London, England)"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00109-014-1148-z","article-title":"Extracellular histones in tissue injury and inflammation","volume":"92","author":"Allam","year":"2014","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0035","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.29271\/jcpsp.2021.11.1337","article-title":"Insulin and heparin therapies in acute pancreatitis due to hypertriglyceridemia","volume":"31","author":"Altinkaya","year":"2021","journal-title":"Jcpsp-Journal of the College of Physicians and Surgeons Pakistan"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.str.2017.01.009","article-title":"Seeing HPV in the new light offers a glimpse of heparin","volume":"25","author":"Angeletti","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.carbpol.2022.119818_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2020.100192","article-title":"The use of heparin and heparin-like molecules in cancer treatment: A review","volume":"24","author":"Atallah","year":"2020","journal-title":"Cancer Treatment and Research Communications"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MAT.0b013e3181c3fec8","article-title":"Cytokines in blood from septic patients interact with surface-immobilized heparin","volume":"56","author":"Axelsson","year":"2010","journal-title":"ASAIO Journal"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0060","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ymben.2012.01.008","article-title":"Metabolic engineering of chinese hamster ovary cells: Towards a bioengineered heparin","volume":"14","author":"Baik","year":"2012","journal-title":"Metabolic Engineering"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0065","first-page":"571","article-title":"CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis","volume":"11","author":"Baumgart","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0070","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.drudis.2020.09.011","article-title":"Advances in the preparation and synthesis of heparin and related products","volume":"25","author":"Baytas","year":"2020","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.carbpol.2022.119818_bb0075","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1021\/acs.jmedchem.0c02019","article-title":"Preparation of low molecular weight heparin from a remodeled bovine intestinal heparin","volume":"64","author":"Baytas","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"21","key":"10.1016\/j.carbpol.2022.119818_bb0080","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1021\/bi052498t","article-title":"Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme","volume":"45","author":"Beckman","year":"2006","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/rmed.1999.0677","article-title":"Inhaled heparin is effective in exacerbations of asthma","volume":"94","author":"Bendstrup","year":"2000","journal-title":"Respiratory Medicine"},{"issue":"17","key":"10.1016\/j.carbpol.2022.119818_bb0090","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.0550-04.2004","article-title":"Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease","volume":"24","author":"Bergamaschini","year":"2004","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.carbpol.2022.119818_bb0095","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1100\/tsw.2009.100","article-title":"Alzheimer's disease: Another target for heparin therapy","volume":"9","author":"Bergamaschini","year":"2009","journal-title":"TheScientificWorldJOURNAL"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s12325-021-01620-1","article-title":"Sulodexide for diabetic-induced disabilities: A systematic review and meta-analysis","volume":"38","author":"Bignamini","year":"2021","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopha.2003.11.007","article-title":"Antitumor and antimetastatic effect of warfarin and heparins","volume":"58","author":"Bobek","year":"2004","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5114\/wo.2013.33766","article-title":"The antineoplastic effect of low-molecular-weight heparins - A literature review","volume":"17","author":"Bochenek","year":"2013","journal-title":"Wspolczesna Onkologia-Contemporary Oncology"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00709-17","article-title":"Identification of heparin modifications and polysaccharide inhibitors of Plasmodium falciparum merozoite invasion that have potential for novel drug development","volume":"61","author":"Boyle","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0120","first-page":"1557","article-title":"Effects of low molecular weight heparin calcium combined with insulin on immune function, inflammatory response, haemorheology and coagulation in patients with high triglyceride acute pancreatitis","volume":"36","author":"Cai","year":"2020","journal-title":"Acta Medica Mediterranea"},{"key":"10.1016\/j.carbpol.2022.119818_bb0125","series-title":"Heparanase: From basic research to clinical applications","first-page":"493","article-title":"Non-anticoagulant heparins as heparanase inhibitors","volume":"1221","author":"Cassinelli","year":"2020"},{"issue":"6","key":"10.1016\/j.carbpol.2022.119818_bb0130","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.matbio.2010.04.003","article-title":"Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer","volume":"29","author":"Casu","year":"2010","journal-title":"Matrix Biology"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0135","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1681\/ASN.V11122324","article-title":"Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats","volume":"11","author":"Ceol","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl. 4","key":"10.1016\/j.carbpol.2022.119818_bb0140","first-page":"103","article-title":"Protective and therapeutic effect of heparin in acute pancreatitis","volume":"59","author":"Ceranowicz","year":"2008","journal-title":"Journal of Physiology and Pharmacology"},{"issue":"16","key":"10.1016\/j.carbpol.2022.119818_bb0145","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1073\/pnas.1910670117","article-title":"Cryo-EM structure of eastern equine encephalitis virus in complex with heparan sulfate analogues","volume":"117","author":"Chen","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.retram.2021.103300","article-title":"Heparin beyond anti-coagulation","volume":"69","author":"Chen","year":"2021","journal-title":"Current Research in Translational Medicine"},{"issue":"7","key":"10.1016\/j.carbpol.2022.119818_bb0155","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aa53c6","article-title":"Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin","volume":"28","author":"Cheng","year":"2017","journal-title":"Nanotechnology"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0160","article-title":"Structural insights into pixatimod (PG545) inhibition of heparanase, a key enzyme in cancer and viral infections","volume":"28","author":"Chhabra","year":"2022","journal-title":"Chemistry"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0165","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.carbpol.2022.119818_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109876","article-title":"A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application","volume":"144","author":"Contini","year":"2020","journal-title":"Medical Hypotheses"},{"issue":"6","key":"10.1016\/j.carbpol.2022.119818_bb0175","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.7861\/clinmed.2020-0351","article-title":"Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19","volume":"20","author":"Conzelmann","year":"2020","journal-title":"Clinical Medicine (London, England)"},{"issue":"9","key":"10.1016\/j.carbpol.2022.119818_bb0180","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3389\/fonc.2019.01316","article-title":"Heparanase: A challenging cancer drug target","volume":"28","author":"Coombe","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"21","key":"10.1016\/j.carbpol.2022.119818_bb0185","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1021\/bi800205t","article-title":"Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1","volume":"47","author":"Copeland","year":"2008","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14656566.2020.1847273","article-title":"An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis","volume":"22","author":"Cosmi","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.carbpol.2022.119818_bb0195","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acssynbio.5b00012","article-title":"CRISPathBrick: Modular combinatorial assembly of type II-A CRISPR arrays for dCas9-mediated multiplex transcriptional repression in E-coli","volume":"4","author":"Cress","year":"2015","journal-title":"ACS Synthetic Biology"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0200","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2020.00483","article-title":"Targeting chemokine-glycosaminoglycan interactions to inhibit inflammation","volume":"31","author":"Crijns","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/j.carbpol.2022.119818_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023007","article-title":"Effects of heparin and enoxaparin on APP processing and a beta production in primary cortical neurons from Tg2576 mice","volume":"6","author":"Cui","year":"2011","journal-title":"PLoS One"},{"issue":"52","key":"10.1016\/j.carbpol.2022.119818_bb0210","doi-asserted-by":"crossref","first-page":"37308","DOI":"10.1074\/jbc.M113.519033","article-title":"Bioengineered Chinese hamster ovary cells with golgi-targeted 3-O-Sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site","volume":"288","author":"Datta","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0215","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/bit.24841","article-title":"An 'omics approach towards CHO cell engineering","volume":"110","author":"Datta","year":"2013","journal-title":"Biotechnology and Bioengineering"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0220","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.CCM.0000059441.70680.DC","article-title":"Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia","volume":"31","author":"Derhaschnig","year":"2003","journal-title":"Critical Care Medicine"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0225","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1021\/acs.orglett.0c01386","article-title":"Programmable one-pot synthesis of heparin pentasaccharide fondaparinux","volume":"22","author":"Dey","year":"2020","journal-title":"Organic Letters"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0230","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.bmcl.2017.04.013","article-title":"Efficient and practical synthesis of Fondaparinux","volume":"27","author":"Ding","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0235","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1016\/j.carbpol.2022.119818_bb0240","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.drudis.2019.06.011","article-title":"LMWH and its derivatives represent new rational for cancer therapy: Construction strategies and combination therapy","volume":"24","author":"Du","year":"2019","journal-title":"Drug Discovery Today"},{"issue":"27","key":"10.1016\/j.carbpol.2022.119818_bb0245","doi-asserted-by":"crossref","first-page":"23671","DOI":"10.18632\/oncotarget.4409","article-title":"Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis","volume":"6","author":"Duckworth","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.carbpol.2022.119818_bb0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.thromres.2021.01.023","article-title":"Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study","volume":"200","author":"Dutch","year":"2021","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0255","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: The RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0260","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: Mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/biomedicines10010049","article-title":"Enoxaparin and pentosan polysulfate bind to the SARS-CoV-2 spike protein and human ACE2 receptor,inhibiting vero cell infection","volume":"10","author":"Ennemoser","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0270","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.mcp.0000174247.23009.06","article-title":"Effect of anticoagulant drugs in cancer","volume":"11","author":"Falanga","year":"2005","journal-title":"Current Opinion in Pulmonary Medicine"},{"key":"10.1016\/j.carbpol.2022.119818_bb0275","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.1074\/jbc.273.22.13563","article-title":"Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma","volume":"273","author":"Fath","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.carbpol.2022.119818_bb0280","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/joim.12604","article-title":"Heparin-binding protein: A key player in the pathophysiology of organ dysfunction in sepsis","volume":"281","author":"Fisher","year":"2017","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.carbpol.2022.119818_bb0285","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.6192498","article-title":"Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone","volume":"221","author":"Folkman","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.carbpol.2022.119818_bb0290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.addr.2015.11.002","article-title":"Bioengineered heparins and heparan sulfates","volume":"97","author":"Fu","year":"2016","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0295","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12871-021-01545-w","article-title":"Unfractionated heparin improves the clinical efficacy in adult sepsis patients: A systematic review and meta-analysis","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Anesthesiology"},{"key":"10.1016\/j.carbpol.2022.119818_bb0300","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2019.06.015","article-title":"Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)","volume":"118","author":"Gezelius","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207387","article-title":"Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin","volume":"13","author":"Gezelius","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.carbpol.2022.119818_bb0310","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.antiviral.2016.12.023","article-title":"Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells","volume":"140","author":"Ghezzi","year":"2017","journal-title":"Antiviral Research"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0315","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12967-018-1621-5","article-title":"Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4\/signal transducer and activator of transcription 6\/Janus kinase 1 pathway","volume":"16","author":"Ghonim","year":"2018","journal-title":"Journal of Translational Medicine"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0320","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/jcp.24677","article-title":"Heparin responses in vascular smooth muscle cells involve cGMP-dependent protein kinase (PKG)","volume":"229","author":"Gilotti","year":"2014","journal-title":"Journal of Cellular Physiology"},{"issue":"147","key":"10.1016\/j.carbpol.2022.119818_bb0325","first-page":"101","article-title":"Hypertriglyceridemia-induced acute pancreatitis: Progress on disease mechanisms and treatment modalities","volume":"27","author":"Guo","year":"2019","journal-title":"Discovery Medicine"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0330","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","article-title":"The platelet-cancer loop","volume":"24","author":"Goubran","year":"2013","journal-title":"European Journal of Internal Medicine"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0335","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.CCM.0000049948.64660.06","article-title":"Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis","volume":"31","author":"Granell","year":"2003","journal-title":"Critical Care Medicine"},{"key":"10.1016\/j.carbpol.2022.119818_bb0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","article-title":"Low molecular weight heparins and their clinical applications","volume":"163","author":"Hao","year":"2019","journal-title":"Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics, Pt B"},{"key":"10.1016\/j.carbpol.2022.119818_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2019.02.002","article-title":"Heparin: An essential drug for modern medicine","volume":"163","author":"Hao","year":"2019","journal-title":"Progress in Molecular Biology and Translational Science"},{"issue":"11","key":"10.1016\/j.carbpol.2022.119818_bb0350","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-021-00962-z","article-title":"Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis","volume":"23","author":"Hernandez","year":"2021","journal-title":"Current Atherosclerosis Reports"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0355","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.carbpol.2011.09.087","article-title":"Photochemical preparation of a novel low molecular weight heparin","volume":"87","author":"Higashi","year":"2012","journal-title":"Carbohydrate Polymers"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/molehr\/gal026","article-title":"Heparin prevents programmed cell death in human trophoblast","volume":"12","author":"Hills","year":"2006","journal-title":"Molecular Human Reproduction"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0365","doi-asserted-by":"crossref","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a therapy for COVID-19: Current evidence and future possibilities","volume":"319","author":"Hippensteel","year":"2020","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233644","article-title":"Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood","volume":"15","author":"Hogwood","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.carbpol.2022.119818_bb0375","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1016\/j.bbadis.2018.07.010","article-title":"Extracellular histones activate autophagy and apoptosis via mTOR signaling in human endothelial cells","volume":"1864","author":"Ibanez-Cabellos","year":"2018","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"issue":"17","key":"10.1016\/j.carbpol.2022.119818_bb0380","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1039\/C9QO00480G","article-title":"Preactivation-based, iterative one-pot synthesis of anticoagulant pentasaccharide fondaparinux sodium","volume":"6","author":"Jin","year":"2019","journal-title":"Organic Chemistry Frontiers"},{"issue":"7811","key":"10.1016\/j.carbpol.2022.119818_bb0385","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M-pro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0390","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jca.21763","article-title":"Therapeutic approaches in hypertriglyceridemia-induced acute pancreatitis: A literature review of available therapies and case series","volume":"35","author":"Joury","year":"2020","journal-title":"Journal of Clinical Apheresis"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0395","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/brv.12034","article-title":"Glycosaminoglycans in infectious disease","volume":"88","author":"Kamhi","year":"2013","journal-title":"Biological Reviews of the Cambridge Philosophical Society"},{"issue":"30","key":"10.1016\/j.carbpol.2022.119818_bb0400","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1016\/j.febslet.2006.11.046","article-title":"Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a\/X1 and 7a\/X4 proteins through NF-kappaB activation","volume":"580","author":"Kanzawa","year":"2006","journal-title":"FEBS Letters"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0405","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/tropicalmed6010026","article-title":"The COVID-19 pandemic: Disproportionate thrombotic tendency and management recommendations","volume":"6","author":"Karim","year":"2021","journal-title":"Tropical Medicine and Infectious Disease"},{"key":"10.1016\/j.carbpol.2022.119818_bb0410","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcrc.2017.11.007","article-title":"Intensive care in severe malaria: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine","volume":"43","author":"Karnad","year":"2018","journal-title":"Critical Care"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0415","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1381612826666201113105250","article-title":"Heparanase inhibitors in cancer progression: Recent advances","volume":"27","author":"Kaur","year":"2021","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138920107779941444","article-title":"Recent developments in tumor angiogenesis","volume":"8","author":"Kilarski","year":"2007","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0425","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/acs.biochem.8b01267","article-title":"Glycosaminoglycan compositional analysis of relevant tissues in Zika virus pathogenesis and in vitro evaluation of heparin as an antiviral against Zika virus infection","volume":"58","author":"Kim","year":"2019","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0430","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acs.biochem.6b01056","article-title":"Interaction of Zika virus envelope protein with glycosaminoglycans","volume":"56","author":"Kim","year":"2017","journal-title":"Biochemistry"},{"issue":"23","key":"10.1016\/j.carbpol.2022.119818_bb0435","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","article-title":"Contaminated heparin associated with adverse clinical events and activation of the contact system","volume":"358","author":"Kishimoto","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0440","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0445","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jiac.2021.11.008","article-title":"The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials","volume":"28","author":"Kow","year":"2022","journal-title":"Journal of Infection and Chemotherapy"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0450","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1570161119666210824160332","article-title":"Thromboprophylaxis in patients with COVID-19: Systematic review of national and international clinical guidance reports","volume":"20","author":"Kyriakoulis","year":"2022","journal-title":"Current Vascular Pharmacology"},{"issue":"3\u20134","key":"10.1016\/j.carbpol.2022.119818_bb0455","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08977194.2021.1895144","article-title":"Attenuating influenza a virus infection by heparin binding EGF-like growth factor","volume":"38","author":"Lai","year":"2020","journal-title":"Growth Factors"},{"issue":"26","key":"10.1016\/j.carbpol.2022.119818_bb0460","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.2174\/0929867324666170216114248","article-title":"Targeting heparan sulfate proteoglycans and their modifying enzymes to enhance anticancer chemotherapy efficacy and overcome drug resistance","volume":"24","author":"Lanzi","year":"2017","journal-title":"Current Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0465","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4269\/ajtmh.2011.10-0256","article-title":"Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates","volume":"84","author":"Leitgeb","year":"2011","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0470","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd724","article-title":"Novel drug development opportunities for heparin","volume":"1","author":"Lever","year":"2002","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"3074","key":"10.1016\/j.carbpol.2022.119818_bb0475","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1126\/science.118.3074.653","article-title":"Effects of intravenous heparin on the plasma lipoproteins in primary hypercholesteremic xanthomatosis and idiopathic hyperlipemia","volume":"118","author":"Lever","year":"1953","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0480","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1471-4159.1998.70020736.x","article-title":"Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide","volume":"70","author":"Leveugle","year":"1998","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.carbpol.2022.119818_bb0485","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.2337\/dc08-s251","article-title":"Abnormal glomerular permeability characteristics in diabetic nephropathy implications for the therapeutic use of low-molecular weight heparin","volume":"31","author":"Lewis","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0490","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/S0021-9258(18)69222-1","article-title":"The sulfate activation locus of Escherichia coli K12: Cloning, genetic, and enzymatic characterization","volume":"263","author":"Leyh","year":"1988","journal-title":"The Journal of Biological Chemistry"},{"issue":"Pt 2","key":"10.1016\/j.carbpol.2022.119818_bb0495","article-title":"Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity","volume":"267","author":"Li","year":"2022","journal-title":"Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0500","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cyto.2014.12.010","article-title":"Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages","volume":"72","author":"Li","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.carbpol.2022.119818_bb0505","first-page":"6275","article-title":"Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review","volume":"9","author":"Li","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.carbpol.2022.119818_bb0510","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12950-020-0238-7","article-title":"Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells","volume":"17","author":"Li","year":"2020","journal-title":"Journal of Inflammation (London, England)"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0515","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.21037\/apm-21-169","article-title":"Therapeutic effect of low-molecular-weight heparin on adult sepsis: A meta-analysis","volume":"10","author":"Li","year":"2021","journal-title":"Annals of Palliative Medicine"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0520","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.14885","article-title":"The role of heparin in sepsis: Much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.carbpol.2022.119818_bb0525","article-title":"Circulating histones in sepsis: Potential outcome predictors and therapeutic targets","volume":"12","author":"Li","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0530","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0166-3542(02)00095-5","article-title":"Heparin inhibits dengue-2 virus infection of five human liver cell lines","volume":"56","author":"Lin","year":"2002","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0535","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1021\/acsinfecdis.9b00425","article-title":"Non-anticoagulant heparin as a pre-exposure prophylaxis prevents Lyme disease infection","volume":"6","author":"Lin","year":"2020","journal-title":"ACS Infectious Diseases"},{"issue":"7\u20139","key":"10.1016\/j.carbpol.2022.119818_bb0540","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1023\/A:1011030711317","article-title":"'Heparin'\u2013from anticoagulant drug into the new biology","volume":"17","author":"Lindahl","year":"2000","journal-title":"Glycoconjugate Journal"},{"key":"10.1016\/j.carbpol.2022.119818_bb0545","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-030-34521-1_2","article-title":"Heparanase - Discovery and targets","volume":"1221","author":"Lindahl","year":"2020","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"9","key":"10.1016\/j.carbpol.2022.119818_bb0550","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/jth.14898","article-title":"Heparin - An old drug with multiple potential targets in Covid-19 therapy","volume":"18","author":"Lindahl","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0555","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000314853","article-title":"Roles of heparin-binding protein in bacterial infections","volume":"2","author":"Linder","year":"2010","journal-title":"Journal of Innate Immunity"},{"key":"10.1016\/j.carbpol.2022.119818_bb0560","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1021\/ar030138x","article-title":"Role of glycosaminoglycans in cellular communication","volume":"37","author":"Linhardt","year":"2004","journal-title":"Accounts of Chemical Research"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0565","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coph.2011.12.002","article-title":"Synthetic heparin","volume":"12","author":"Linhardt","year":"2012","journal-title":"Current Opinion in Pharmacology"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0570","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Natural Product Reports"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0575","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1039\/C4NP00076E","article-title":"Chemoenzymatic synthesis of heparan sulfate and heparin","volume":"31","author":"Liu","year":"2014","journal-title":"Natural Product Reports"},{"issue":"19","key":"10.1016\/j.carbpol.2022.119818_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910730","article-title":"Molecular mechanism of the anti-inflammatory action of heparin","volume":"22","author":"Litov","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"15","key":"10.1016\/j.carbpol.2022.119818_bb0585","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2174\/138161207780765918","article-title":"Heparin oligosaccha rides as potential therapeutic agents in senile dementia","volume":"13","author":"Ma","year":"2007","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0590","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: A review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adhesion & Migration"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0595","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14656566.5.2.329","article-title":"Drug treatment of ulcerative colitis: Unfractionated heparin, low molecular weight heparins and beyond","volume":"5","author":"Malhotra","year":"2004","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0600","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.nano.2014.06.002","article-title":"Application of heparin as a dual agent with antimalarial and liposome targeting activities toward Plasmodium-infected red blood cells","volume":"10","author":"Marques","year":"2014","journal-title":"Nanomedicine-Nanotechnology Biology and Medicine"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0605","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph10040078","article-title":"Heparin mimetics: Their therapeutic potential","volume":"10","author":"Mohamed","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.carbpol.2022.119818_bb0610","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/856341","article-title":"Current status of new anticoagulants in the management of venous thromboembolism","volume":"2012","author":"Montoya","year":"2012","journal-title":"Advances in Hematology"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0615","first-page":"1963","article-title":"Glycosaminoglycans and glycosaminoglycan mimetics in cancer and inflammation","volume":"20","author":"Morla","year":"2019","journal-title":"International Journal of Biological Macromolecules"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0620","first-page":"1006","article-title":"Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence (vol 102, pg 258, 2009)","volume":"102","author":"Mousa","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.carbpol.2022.119818_bb0625","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/507151","article-title":"Anti-inflammatory effects of heparin and its derivatives: A systematic review","volume":"2015","author":"Mousavi","year":"2015","journal-title":"Advances in Pharmacological Sciences"},{"key":"10.1016\/j.carbpol.2022.119818_bb0630","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coph.2019.03.009","article-title":"The non-anticoagulant promise of heparin and its mimetics","volume":"46","author":"Mulloy","year":"2019","journal-title":"Current Opinion in Pharmacology"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0635","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/md17050293","article-title":"A glycosaminoglycan extract from Portunus pelagicus inhibits BACE1, the beta secretase implicated in Alzheimer's disease","volume":"17","author":"Mycroft-West","year":"2019","journal-title":"Marine Drugs"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0640","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/md19040203","article-title":"Glycosaminoglycans from Litopenaeus vannamei inhibit the Alzheimer's disease beta secretase, BACE1","volume":"19","author":"Mycroft-West","year":"2021","journal-title":"Marine Drugs"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0645","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4103\/1673-5374.274341","article-title":"Inhibition of BACE1, the beta-secretase implicated in Alzheimer's disease, by a chondroitin sulfate extract from Sardina pilchardus","volume":"15","author":"Mycroft-West","year":"2020","journal-title":"Neural Regeneration Research"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0650","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: Structural dependence of the interaction of the spike S1 receptor-binding domain with heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"issue":"9","key":"10.1016\/j.carbpol.2022.119818_bb0655","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.2337\/db06-0221","article-title":"RAGE control of diabetic nephropathy in a mouse model: Effects of RAGE gene disruption and administration of low-molecular weight heparin","volume":"55","author":"Myint","year":"2006","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0660","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10529-011-0840-0","article-title":"Removing human immunodeficiency virus (HIV) from human blood using immobilized heparin","volume":"34","author":"Nassar","year":"2012","journal-title":"Biotechnology Letters"},{"issue":"7","key":"10.1016\/j.carbpol.2022.119818_bb0665","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and anticoagulation","volume":"21","author":"Onishi","year":"2016","journal-title":"Frontiers in Bioscience Landmark"},{"issue":"12","key":"10.1016\/j.carbpol.2022.119818_bb0670","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with Nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase I results","volume":"22","author":"O'Reilly","year":"2017","journal-title":"The Oncologist"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0675","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph9030038","article-title":"Heparin: Past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"issue":"20","key":"10.1016\/j.carbpol.2022.119818_bb0680","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1021\/jm051221o","article-title":"Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor xa and other proteases","volume":"49","author":"Patey","year":"2006","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1\u20132","key":"10.1016\/j.carbpol.2022.119818_bb0685","first-page":"65","article-title":"Anticoagulant and clearing effects of heparin in hyperlipemia","volume":"8","author":"Pinter","year":"1957","journal-title":"Magyar Tudom\u00e1ny"},{"issue":"18","key":"10.1016\/j.carbpol.2022.119818_bb0690","doi-asserted-by":"crossref","first-page":"10028","DOI":"10.1128\/JVI.00051-12","article-title":"Heparan sulfate is an attachment factor for foamy virus entry","volume":"86","author":"Plochmann","year":"2012","journal-title":"Journal of Virology"},{"key":"10.1016\/j.carbpol.2022.119818_bb0695","first-page":"1","article-title":"Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: Data from the multicentre observational START-COVID register","volume":"1","author":"Poli","year":"2022","journal-title":"Internal and Emergency Medicine"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0700","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1568026615666150605104444","article-title":"Antimicrobial sulfated glycans: Structure and function","volume":"17","author":"Pomin","year":"2017","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0705","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1160\/TH16-08-0620","article-title":"More than an anticoagulant: Do heparins have direct anti-inflammatory effects?","volume":"117","author":"Poterucha","year":"2017","journal-title":"Thrombosis and Haemostasis"},{"issue":"7","key":"10.1016\/j.carbpol.2022.119818_bb0710","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/1381612033391379","article-title":"Heparin derivatives as angiogenesis inhibitors","volume":"9","author":"Presta","year":"2003","journal-title":"Current Pharmaceutical Design"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0715","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.3892\/mmr.2016.5719","article-title":"Heparin inhibits the inflammation and proliferation of human rheumatoid arthritis fibroblast-like synoviocytes through the NF-kappa B pathway","volume":"14","author":"Qi","year":"2016","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.carbpol.2022.119818_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.121270","article-title":"Recent advances in biotechnology for heparin and heparan sulfate analysis","volume":"219","author":"Qiao","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.carbpol.2022.119818_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111561","article-title":"Pharmacological and clinical application of heparin progress: An essential drug for modern medicine","volume":"139","author":"Qiu","year":"2021","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.carbpol.2022.119818_bb0730","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.carbpol.2022.119818_bb0735","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.07.008","article-title":"A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models","volume":"195","author":"Ripsman","year":"2020","journal-title":"Thrombosis Research"},{"issue":"20","key":"10.1016\/j.carbpol.2022.119818_bb0740","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2174\/138161207781039689","article-title":"Fibroblast growth Factors\/Fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies","volume":"13","author":"Rusnati","year":"2007","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11592870-000000000-00000","article-title":"Potential beneficial effects of low molecular weight heparin on cognitive impairment in elderly patients on haemodialysis","volume":"29","author":"Sain","year":"2012","journal-title":"Drugs & Aging"},{"key":"10.1016\/j.carbpol.2022.119818_bb0750","first-page":"1","article-title":"Heparin 2.0: A new approach to the infection crisis","author":"Seffer","year":"2020","journal-title":"Blood Purification"},{"key":"10.1016\/j.carbpol.2022.119818_bb0755","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fimmu.2012.00293","article-title":"Glycosaminoglycan analogs as a novel anti-inflammatory strategy","volume":"3","author":"Severin","year":"2012","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/j.carbpol.2022.119818_bb0760","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-017-0738-6","article-title":"Redefining approaches to asthma: Bridging the gap between heparin and its anti-inflammatory activities","volume":"17","author":"Shastri","year":"2017","journal-title":"Current Allergy and Asthma Reports"},{"key":"10.1016\/j.carbpol.2022.119818_bb0765","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijbiomac.2019.04.019","article-title":"Development of low molecular weight heparin by H2O2\/ascorbic acid with ultrasonic power and its anti-metastasis property","volume":"133","author":"Shen","year":"2019","journal-title":"International Journal of Biological Macromolecules"},{"issue":"6","key":"10.1016\/j.carbpol.2022.119818_bb0770","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cts.12880","article-title":"The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: A retrospective cohort study","volume":"13","author":"Shi","year":"2020","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.carbpol.2022.119818_bb0775","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.639666","article-title":"Glycosaminoglycan-protein interactions and their roles in human disease","volume":"8","author":"Shi","year":"2021","journal-title":"Frontiers in Molecular Biosciences"},{"key":"10.1016\/j.carbpol.2022.119818_bb0780","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2018.01.006","article-title":"Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD","volume":"40","author":"Shute","year":"2018","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.carbpol.2022.119818_bb0785","doi-asserted-by":"crossref","first-page":"25376","DOI":"10.1074\/jbc.M704698200","article-title":"Mosquito heparan sulfate and its potential role in malaria infection and transmission","volume":"282","author":"Sinnis","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0790","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1039\/C4MD00516C","article-title":"Inhibition of influenza H5N1 invasion by modified heparin derivatives","volume":"6","author":"Skidmore","year":"2015","journal-title":"Medchemcomm"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0795","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(24)01481-9","article-title":"The complex effects of heparins on cancer progression and metastasis in experimental studies","volume":"53","author":"Smorenburg","year":"2001","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.carbpol.2022.119818_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.710683","article-title":"The unifying hypothesis of Alzheimer's disease: Heparan sulfate proteoglycans\/glycosaminoglycans are key as first hypothesized over 30 years ago","volume":"13","author":"Snow","year":"2021","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/j.carbpol.2022.119818_bb0805","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","article-title":"Lyme borreliosis","volume":"2","author":"Steere","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"10","key":"10.1016\/j.carbpol.2022.119818_bb0810","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1074\/jbc.RA119.010353","article-title":"A synthetic heparinoid blocks tau aggregate cell uptake and amplification","volume":"295","author":"Stopschinski","year":"2020","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.carbpol.2022.119818_bb0815","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.carbpol.2022.119818_bb0820","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2021.01.007","article-title":"Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties","volume":"54","author":"Tang","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0825","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jth.14821","article-title":"The versatile heparin in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0830","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0835","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.nbd.2010.06.008","article-title":"Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe\/PS1dE9 mice with differential effects on brain a beta levels","volume":"40","author":"Timmer","year":"2010","journal-title":"Neurobiology of Disease"},{"issue":"Suppl. 1","key":"10.1016\/j.carbpol.2022.119818_bb0840","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0167-5273(16)12001-7","article-title":"Heparin centenary - An ever-young life-saving drug","volume":"212","author":"Torri","year":"2016","journal-title":"International Journal of Cardiology"},{"issue":"24","key":"10.1016\/j.carbpol.2022.119818_bb0845","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.3390\/molecules26247488","article-title":"HIV-1 Tat and heparan sulfate proteoglycans orchestrate the setup of in Cis and in trans cell-surface interactions functional to lymphocyte trans-endothelial migration","volume":"26","author":"Urbinati","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.carbpol.2022.119818_bb0850","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/molecules22061025","article-title":"From farm to pharma: An overview of industrial heparin manufacturing methods","volume":"22","author":"van der Meer","year":"2017","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.carbpol.2022.119818_bb0855","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1111\/bcp.14714","article-title":"Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients","volume":"87","author":"van Haren","year":"2022","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"13","key":"10.1016\/j.carbpol.2022.119818_bb0860","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1074\/jbc.M113.541441","article-title":"Heparin prevents intracellular hyaluronan synthesis and autophagy responses in hyperglycemic dividing mesangial cells and activates synthesis of an extensive extracellular monocyte-adhesive hyaluronan matrix after completing cell division","volume":"289","author":"Wang","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.carbpol.2022.119818_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.586652","article-title":"Heparin attenuates histone-mediated cytotoxicity in septic acute kidney injury","volume":"7","author":"Wang","year":"2020","journal-title":"Frontiers in Medicine"},{"issue":"18","key":"10.1016\/j.carbpol.2022.119818_bb0870","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.2165\/00003495-200767180-00004","article-title":"The role of sulodexide in the treatment of diabetic nephropathy","volume":"67","author":"Weiss","year":"2007","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.carbpol.2022.119818_bb0875","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2013-07-514984","article-title":"Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis","volume":"123","author":"Wildhagen","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0880","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12985-019-1246-1","article-title":"Heparin sulfate is the attachment factor of duck tembus virus on both BHK21 and DEF cells","volume":"16","author":"Wu","year":"2019","journal-title":"Virology Journal"},{"issue":"6055","key":"10.1016\/j.carbpol.2022.119818_bb0885","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.1207478","article-title":"Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins","volume":"334","author":"Xu","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0890","doi-asserted-by":"crossref","first-page":"00741","DOI":"10.1183\/23120541.00741-2020","article-title":"Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19","volume":"7","author":"Xue","year":"2021","journal-title":"ERJ Open Research"},{"key":"10.1016\/j.carbpol.2022.119818_bb0895","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carbpol.2016.12.037","article-title":"Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review","volume":"160","author":"Yan","year":"2017","journal-title":"Carbohydrate Polymers"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0900","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/aas.12418","article-title":"Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model","volume":"59","author":"Yini","year":"2015","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"6","key":"10.1016\/j.carbpol.2022.119818_bb0905","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1016\/j.carbpol.2022.119818_bb0910","doi-asserted-by":"crossref","first-page":"E504","DOI":"10.1097\/PEC.0000000000002645","article-title":"Potential of heparin in the treatment of COVID-19-associated myocarditis","volume":"38","author":"Yu","year":"2022","journal-title":"Pediatric Emergency Care"},{"issue":"5","key":"10.1016\/j.carbpol.2022.119818_bb0915","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0973-1482.191627","article-title":"Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis","volume":"12","author":"Yu","year":"2016","journal-title":"Journal of Cancer Research and Therapeutics"},{"issue":"3c","key":"10.1016\/j.carbpol.2022.119818_bb0920","first-page":"2789","article-title":"Low-molecular-weight heparin in oncology","volume":"23","author":"Zacharski","year":"2003","journal-title":"Anticancer Research"},{"issue":"1","key":"10.1016\/j.carbpol.2022.119818_bb0925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.chest.2018.09.020","article-title":"VTE risk profiles and prophylaxis in medical and surgical inpatients the identification of Chinese hospitalized patients' risk profile for venous thromboembolism (DissolVE-2)-a cross-sectional study","volume":"155","author":"Zhai","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.carbpol.2022.119818_bb0930","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41421-020-00222-5","article-title":"Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discovery"},{"issue":"39","key":"10.1016\/j.carbpol.2022.119818_bb0935","doi-asserted-by":"crossref","first-page":"12998","DOI":"10.1021\/ja8026345","article-title":"Solution structures of chemoenzymatically synthesized heparin and its precursors","volume":"130","author":"Zhang","year":"2008","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.carbpol.2022.119818_bb0940","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1073\/pnas.1902227116","article-title":"Circulating heparin oligosaccharides rapidly target the hippocampus in sepsis potentially impacting cognitive functions","volume":"116","author":"Zhang","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.carbpol.2022.119818_bb0945","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ultsonch.2018.11.016","article-title":"Preparation of low molecular weight heparin using an ultrasound-assisted Fenton-system","volume":"52","author":"Zhi","year":"2019","journal-title":"Ultrasonics Sonochemistry"},{"key":"10.1016\/j.carbpol.2022.119818_bb0950","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/anie.201913029","article-title":"3-O-sulfation of heparan sulfate enhances tau interaction and cellular uptake","volume":"59","author":"Zhao","year":"2020","journal-title":"Angewandte Chemie International Edition"}],"container-title":["Carbohydrate Polymers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0144861722007238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0144861722007238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:26:43Z","timestamp":1778718403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0144861722007238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":189,"alternative-id":["S0144861722007238"],"URL":"https:\/\/doi.org\/10.1016\/j.carbpol.2022.119818","relation":{},"ISSN":["0144-8617"],"issn-type":[{"value":"0144-8617","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin: An old drug for new clinical applications","name":"articletitle","label":"Article Title"},{"value":"Carbohydrate Polymers","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carbpol.2022.119818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"119818"}}